CD-200 induces apoptosis and inhibits Bcr-Abl signaling in imatinib-resistant chronic myeloid leukemia with T315I mutation

Medicine and Dentistry

• Programmed Cell Death 100%
• Chronic Myelogenous Leukemia 100%
• Imatinib 100%
• Imatinib Resistance 40%
• Signal Transduction 40%
• Diseases 20%
• Cell Proliferation 20%
• Cell Survival 20%
• Tumor Progression 20%
• Xenograft 20%
• Leukemia Cell 20%
• Antiinflammatory Activity 20%
• Mitochondrial Membrane Potential 20%
• Antiproliferative Activity 20%
• Natural Product 20%
• Poly ADP Ribose Polymerase 20%
• Antioxidant Capacity 20%
• Point Mutation 20%
• Abelson Kinase 20%
• Caspase 3 20%

Biochemistry, Genetics and Molecular Biology

• Myeloid 100%
• Imatinib 100%
• Signal Transduction 33%
• Liriodendron 33%
• Wild Type 16%
• Tyrosine Kinase 16%
• Anticancer 16%
• Point Mutation 16%
• Cell Proliferation 16%
• Antioxidant Activity 16%
• Cell Survival 16%
• Mitochondrial Membrane Potential 16%
• Antiproliferative Activity 16%
• Antiinflammatory Activity 16%
• Receptor Tyrosine Kinase 16%
• Tumor Progression 16%
• Caspase 3 16%
• Poly ADP Ribose Polymerase 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Chronic Myeloid Leukemia 100%
• Imatinib 100%
• Liriodendron 33%
• Antiinflammatory Activity 16%
• Antioxidant Capacity 16%
• Tumor Growth 16%
• Abelson Kinase 16%
• Natural Product 16%
• Disease 16%
• Caspase 3 16%